Non-alcoholic fatty liver disease and the myocardial remodeling: the role of insulin resistance in the hepatocardial association development
https://doi.org/10.31146/1682-8658-ecg-177-5-47-52
Abstract
Aim. The aim of the study was to assess glucose metabolism, its perfusion in the cardiomyocytes and the detection of the myocardial dysfunction in patients with fatty liver disease and insulin resistance using the positron emission tomography with fl udeoxyglucose.
Materials and methods. In our study patients with the non-alcoholic fatty liver disease and the insulin resistance were examined. All patients underwent the еchocardiography and the positron emission tomography scans for myocardial dysfunction assessment.
Results and discussion. Echocardiography revealed various types of the left ventricular cardiac remodeling. The positron emission tomography showed a pronounced diffuse uneven distribution of the radiopharmaceutical. In addition, zones of hypometabolism and paradoxical accumulation of glucose were detected. It`s important to note that these indicated zones did not form sectors around a specifi c artery area, possibly refl ecting zones of fatty infi ltration or fi brotic changes in the myocardium. Thus, it was shown that in patients with the non-alcoholic fatty liver disease and insulin resistance the intensity and nature of glucose metabolism in cardiomyocytes were changed, indicating the presence of myocardial metabolic dysfunction.
Conclusion. We believe that in systemic insulin resistance metabolic processes were disturbed not only in the liver cells, but also in the cardiomyocytes, the rate of glucose utilization and its transmembrane transfer into cardiomyocytes were changed. As a result of the metabolic dysfunction, the geometric parameters of the heart are changed and various types of the cardiac remodelling are formed.
About the Authors
G. E. Rojtberg
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Grigory E. Rojtberg, Academician of the Russian Academy of Sciences, Doc. of Med. Sci., Professor, Chief of the Department of Therapy, General Practice and Nuclear Medicine
117997, Moscow
O. O. Sharkhun
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Olga O. Sharkhun, Cand. of Med. Sci., Associate Professor of the Department of Therapy, General Practice and Nuclear
Medicine
117997, Moscow
References
1. Усов В. Ю., Архангельский В. А., Федоренко Е. В. Оценка жизнеспособности поврежденного миокарда у кардиохирургических больных: сравнение возможностей магнитно-резонансной и эмиссионной томографии // Комплексные проблемы сердечно-сосудистых заболеваний. – 2014. – Т. 3. – С. 124–132. Usov W. Y., Arkhangelsky V. A., Fedorenko E. V. Detection of myocardial viability in isсhaemic damage in cardiac surgery: comparison of possibilities of magnetic resonance and emission tomography. Complex Issues of Cardiovascular Diseases. 2014;(3):124–133. (In Russ.) https://doi.org/10.17802/2306-1278-2014-3-124-133.
2. Бузиашвили Ю. И., Бузиашвили В. Ю. Возможности современных методик визуализации при ишемической болезни сердца // Кардиосоматика. – 2014. – Т. 3(4). – С. 20–26. Buziashvili Yu.I, Buziashvil V. Yu. Stable coronary artery disease – opportunities of non-invasivevisualization. Kardiosomatika (Cardiosomatics). 2014;3(4):20–26.
3. Никифоров В. С. Методы сердечно-сосудистой визуализации в диагностике ишемической болезни сердца // Сonsilium medicum. – 2017. – Т. 19(1). – С. 18–24. Nikiforov V. S. Methods of cardiovascular imaging for the detection of ischemic heart disease. Consilium Medicum. 2017;19(1):18–24.
4. Пармон Е. В., Рыжкова Д. В. Оценка состояния метаболизма и перфузии миокарда при некоронарогенных желудочковых нарушениях ритма // Артериальная гипертензия. – 2014. – Т. 20(3). – С. 189–200. Parmon E. V., Ryzhkova D. V. Assessment of perfusion and metabolism of myocardium in noncoronarogenic ventricular arrhythmia. Arterial Hypertension. 2014;20(3):189–200. (In Russ.) https://doi.org/10.18705/1607-419X-2014-20-3-189-200.
5. Бокерия Л. А., Шурупова И. В., Асланиди И. П. и др. Оценка перфузии и метаболизма у больных с дилатационной кардиомиопатией // Креативная кардиология. – 2010. – № 1. – С. 43–54. Bokeria L. A., Shurupova I. V., Aslanidis I. P. et al. Evaluation of perfusion and metabolism in dilated cardiomyopathy patients. Creative cardiology, 2010, no. 1, pp. 43–54.
6. Ройтберг Г.Е., Шархун О. О. Оценка факторов риска неалкогольной жировой болезни печени // Лечащий врач. – 2017. – Т. 1. – С. 58–62. Roitberg G. E., Sharhun O. O. Assessment of risk factors for nonalcoholic fatty liver disease. Lvrach, 2017, vol.1, pp. 58–62.
7. Лазебник Л. Б., Радченко В. Г., Голованова Е. В. и др. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение (рекомендации для терапевтов, 2-я версия) // Терапия. – 2017. – № 3 (13). – С. 5–23. Lazebnik L. B., Radchenko V. G., Golovanova Ye.V. et al. Nonalcoholic fatty liver disease: clinic, diagnostics, treatment (guidelines for the specialists on internal medicine, 2nd version). Therapy, 2017, no. 3 (13), pp. 5–23.
8. Ройтберг Г. Е., Шархун О. О. Особенности прогрессирования поражения печени при инсулинорезистентности // Медицинский альманах. – 2017. – Т. 1(46). – С. 65–8. Roitberg G. E., Sharhun O. O. Features of the liver damage progression in insulin resistance patients. Medical Almanakh, 2017, vol.1(46), pp. 65–8.
9. Bonapace S., Perseghin G., Molon G. et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care. 2012;35(2):389–395.
10. Mantovani A., Pernigo M., Bergmini C. et al. Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes. PLoS ONE. 2015;10(8):234–239. doi: 10.1371/journal.pone.0135329.
11. Treeprasertsuk S., Björnsson E., Enders F. et al. NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol. 2013;19(8):1219–1229. doi: 10.3748/wjg.v19.i8.1219.
12. Musso G., Cassader M., Rosina F. et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55(4):885–904. doi: 10.1007/s00125-011-2446-4.
13. Драпкина О. М. РААС и фиброз. Гепатокардиальные связи // Русский медицинский журнал. – 2011. – Т. 18(19). – С. 1136–9. Drapkina O. M. RAAS and fibrosis. Hepatocardial connections. Russian Medical Journal, 2011, vol. 18(19), pp. 1136–9.
14. Altehoefer С., vom Dahl J., Bares R. et al. Metabolic mismatch of septal betaoxidation and glucose utilization in left bundle branch block assessed with PET. J Nucl Med. 1995;36(11):2056–2059.
15. Yamamoto S., James T. N., Kawamura K. et al. Cardiocytic apoptosis and cappilary endothelian swelling as morphological evidence of myocardial ischemia in ventricular biopsies from patients with angina and normal arteriograms. Coron. Artery Dis. 2002;13(1):25–35.
16. Yoshinaga R., Tamaki N. Imaging myocardial metabolism. Gurr. Opin.Biotechnol. 2007;18(1):52–59.
Review
For citations:
Rojtberg G.E., Sharkhun O.O. Non-alcoholic fatty liver disease and the myocardial remodeling: the role of insulin resistance in the hepatocardial association development. Experimental and Clinical Gastroenterology. 2020;174(5):47-52. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-177-5-47-52
Views:
495
Email this article 